A Review of the Prevention of Mother-to-Child Transmission of Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1) With a Proposed Management Algorithm.
HTLV-1
adult T cell lymphoma/leukemia
antiretrovirals
neonate
pregnancy
prevention of mother-to-child transmission
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
05
2022
accepted:
10
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Human T cell lymphotropic virus type 1 (HTLV-1) is a human retrovirus that is endemic in a number of regions across the world. There are an estimated 5-10 million people infected worldwide. Japan is currently the only country with a national antenatal screening programme in place. HTLV-1 is primarily transmitted sexually in adulthood, however it can be transmitted from mother-to-child perinatally. This can occur transplacentally, during the birth process or via breastmilk. If HTLV-1 is transmitted perinatally then the lifetime risk of adult T cell leukemia/lymphoma rises from 5 to 20%, therefore prevention of mother-to-child transmission of HTLV-1 is a public health priority. There are reliable immunological and molecular tests available for HTLV-1 diagnosis during pregnancy and screening should be considered on a country by country basis. Further research on best management is needed particularly for pregnancies in women with high HTLV-1 viral load. A first step would be to establish an international registry of cases and to monitor outcomes for neonates and mothers. We have summarized key risk factors for mother-to-child transmission of HTLV-1 and subsequently propose a pragmatic guideline for management of mothers and infants in pregnancy and the perinatal period to reduce the risk of transmission. This is clinically relevant in order to reduce mother-to-child transmission of HTLV-1 and it's complications.
Identifiants
pubmed: 35872787
doi: 10.3389/fmed.2022.941647
pmc: PMC9304803
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
941647Informations de copyright
Copyright © 2022 Barr, Drysdale, Boullier, Lyall, Cook, Collins, Kelly, Phelan and Taylor.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Hum Virol. 1998 May-Jun;1(4):302-5
pubmed: 10195256
Br J Haematol. 2019 Mar;184(6):1040-1043
pubmed: 29676441
Blood. 2012 Oct 25;120(17):3488-90
pubmed: 22955925
J Obstet Gynaecol Res. 2004 Dec;30(6):436-8
pubmed: 15566458
Leukemia. 1997 Apr;11 Suppl 3:60-2
pubmed: 9209298
Int J Cancer. 1990 Feb 15;45(2):237-43
pubmed: 2303290
Jpn J Cancer Res. 1986 Oct;77(10):974-7
pubmed: 2877963
Microorganisms. 2021 Jun 30;9(7):
pubmed: 34209130
IARC Monogr Eval Carcinog Risks Hum. 1994;59:1-255
pubmed: 7933461
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):167-70
pubmed: 9473019
Sci Rep. 2018 May 17;8(1):7742
pubmed: 29773807
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):193-201
pubmed: 8680892
ARYA Atheroscler. 2018 Jul;14(4):183-187
pubmed: 30627195
Viruses. 2016 Feb 03;8(2):
pubmed: 26848683
J Infect Dis. 2006 Jan 15;193(2):277-82
pubmed: 16362892
J Virol. 2001 Sep;75(18):8461-8
pubmed: 11507191
Pediatr Int. 2021 Mar;63(3):284-289
pubmed: 32574414
Front Microbiol. 2018 Mar 13;9:278
pubmed: 29593659
Transfusion. 2002 Jun;42(6):780-91
pubmed: 12147033
J Clin Invest. 1987 Aug;80(2):394-400
pubmed: 3038956
BMJ. 2000 Mar 4;320(7235):611-2
pubmed: 10698878
Antimicrob Agents Chemother. 2011 May;55(5):2011-7
pubmed: 21343468
PLoS Negl Trop Dis. 2018 Nov 12;12(11):e0006913
pubmed: 30418973
J Clin Oncol. 2019 Mar 10;37(8):677-687
pubmed: 30657736
Viruses. 2016 Feb 03;8(2):
pubmed: 26848684
J Clin Microbiol. 1990 Sep;28(9):1988-93
pubmed: 2229382
Exp Ther Med. 2021 Jan;21(1):82
pubmed: 33363593
J Virol. 1999 Dec;73(12):10289-95
pubmed: 10559346
J Antimicrob Chemother. 2012 Jan;67(1):218-21
pubmed: 21965433
Blood. 2015 Dec 10;126(24):2570-7
pubmed: 26361794
J Clin Invest. 2020 Nov 2;130(11):6171-6186
pubmed: 33074247
Lancet Infect Dis. 2020 Jan;20(1):133-143
pubmed: 31648940
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
Br J Haematol. 2011 May;153(4):451-85
pubmed: 21480860
J Clin Exp Hematop. 2019;59(4):156-167
pubmed: 31866618
J Med Virol. 2015 Dec;87(12):2130-4
pubmed: 25982784
Rev Inst Med Trop Sao Paulo. 1998 Jul-Aug;40(4):245-51
pubmed: 9876439
Virus Res. 2001 Oct 30;78(1-2):93-100
pubmed: 11520583
Trop Med Int Health. 2019 Aug;24(8):934-953
pubmed: 31183938
PLoS Negl Trop Dis. 2019 Sep 12;13(9):e0007736
pubmed: 31513603
Front Microbiol. 2019 May 08;10:999
pubmed: 31134031
J Infect. 1989 Jul;19(1):25-9
pubmed: 2778340
J Infect Dis. 2005 May 1;191(9):1490-7
pubmed: 15809908
Retrovirology. 2005 Mar 02;2:17
pubmed: 15743526
Front Microbiol. 2020 Apr 09;11:595
pubmed: 32328047
Int J Cancer. 1996 Apr 10;66(2):197-200
pubmed: 8603811
Leuk Res. 1990;14(10):841-7
pubmed: 2259221
Blood Adv. 2020 May 12;4(9):2044-2048
pubmed: 32396612
J Infect Dis. 1993 Jan;167(1):57-65
pubmed: 8418183
Clin Infect Dis. 2002 Jun 15;34(12):1551-7
pubmed: 12032888
Rev Panam Salud Publica. 2007 Oct;22(4):223-30
pubmed: 18078583
EJHaem. 2020 Nov 25;2(1):131-135
pubmed: 35846087
Cancers (Basel). 2021 Aug 14;13(16):
pubmed: 34439253